Juli 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics og GenScript ProBio er i ferd med å signere en kontrakt for utvikling og produksjon av plasmid- og virusvektorer for den første rørledningen til ACT Therapeutics' Advanced CAR-T Platform (ACT-plattform), som også vil få i oppdrag å produsere råvarer for ACT Therapeutics' påfølgende rørledninger. Kontrakten vil dekke produksjon av plasmider og virusvektorer for den første rørledningen til ACT Therapeutics' Advanced CAR-T-plattform.
Som et resultat av denne avtalen har GenScript ProBio blitt hevet til status som en global partner som er i stand til å støtte ACT-plattformer for ACT-terapi.
ACT-plattformen er en neste generasjons celle- og genterapiteknologi som retter seg mot kreftantigener ved å sette inn gener designet for å målrette disse antigenene inn i immunceller. Disse genene leveres inn i immunceller ved bruk av virusvektorer. GenScript ProBio har en høykvalitets virusvektorprosessutvikling og en one-stop serviceplattform for GMP-produksjon, som begge er nødvendige for utvikling av celle- og genterapi.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing blodkreft. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, administrerende direktør i ACT Therapeutics, sa: "Vi har fullført forberedelsene til at ACT-plattformen skal dukke opp globalt gjennom et strategisk partnerskap med GenScript ProBio. Vi vil fremskynde utviklingen av behandlinger rettet mot ildfaste og vanskelige solide kreftformer."
Om GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Mot oppdraget "Innovasjon gjennom samarbeid", er GenScript ProBio forpliktet til å hjelpe kunder med å forkorte tidslinjen for utvikling av biologiske legemidler fra oppdagelse til kommersialisering, redusere FoU-kostnadene betydelig og bygge en sunnere fremtid.
